Clinical Trials Logo

Filter by:
NCT ID: NCT02926768 Completed - Clinical trials for Carcinoma, Non-Small-Cell Lung

Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors

Start date: September 2016
Phase: Phase 1
Study type: Interventional

CK-101 is a novel, potent, small molecule tyrosine kinase inhibitor (TKI) that selectively targets mutant forms of the epidermal growth factor receptor (EGFR) while sparing wild-type (WT) EGFR. The purpose of the study is to evaluate the pharmacokinetic (PK) and safety profile of oral CK-101; to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of oral CK-101; to assess the safety and efficacy of CK-101 in treatment-naive NSCLC patients known to have activating EGFR mutations and previously treated NSCLC patients known to have the T790M EGFR mutation.

NCT ID: NCT02926131 Completed - Jaundice Clinical Trials

A Study to Evaluate a New Jaundice Stick Test

Bilistick
Start date: January 25, 2017
Phase:
Study type: Observational

This is an observational prospective study. The main purpose is to evaluate the stability of the Bilistick system in a humid and hot climate compared to the quantitative test for serum bilirubin (SBR) measurement currently used, the BR-501 total bilirubin meter, kept in a controlled environment. The secondary aim is to assess the operational feasibility of the Bilistick system in a tropical limited-resource setting, when used by locally trained nurses.

NCT ID: NCT02924727 Completed - Clinical trials for Acute Myocardial Infarction

Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI

PARADISE-MI
Start date: December 9, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of LCZ696 titrated to a target dose of 200 mg twice daily, compared to ramipril titrated to a target dose of 5 mg twice daily.

NCT ID: NCT02924376 Completed - Cholangiocarcinoma Clinical Trials

Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)

Start date: January 16, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is evaluate the efficacy of pemigatinib in subjects with advanced/metastatic or surgically unresectable cholangiocarcinoma with FGFR2 translocation who have failed at least 1 previous treatment.

NCT ID: NCT02922244 Completed - Breast Neoplasms Clinical Trials

Effects of Herbal Products on Reduction of Radiation-induced Dermatitis in Breast Cancer Patients

Start date: May 2016
Phase: N/A
Study type: Interventional

The herbal products on reduction of radiation-induced dermatitis in patients with breast cancer

NCT ID: NCT02919514 Completed - Aging Clinical Trials

Effect of Surfaces on Fall in Elderly

Start date: November 15, 2015
Phase: N/A
Study type: Interventional

To investigate the effects of Thai dance exercises over 6 weeks on functional outcomes and incidence of fall in community-dwelling older individuals. To compare effects of exercise training on hard, soft and sand surfaces in community-dwelling older individuals

NCT ID: NCT02919306 Completed - Clinical trials for Human Immunodeficiency Virus

Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults

Start date: September 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the study is to assess: 1 safety and tolerability of adenovirus serotype 26 (Ad26) prime and Modified Vaccinia Ankara (MVA) boost versus placebo in participants on suppressive antiretroviral therapy (ART) that was initiated during acute Human Immunodeficiency Virus (HIV) infection; 2) Measure the frequency and duration of sustained viremic control after receiving Ad26 prime/MVA boost or placebo, defined as greater than 24 weeks with plasma HIV ribonucleic acid (RNA) lesser than (<)50 copies/ml after antiretroviral (ARV) analytical treatment interruption (ATI).

NCT ID: NCT02917031 Completed - Heart Failure Clinical Trials

Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure

MEASURE-HF
Start date: January 10, 2017
Phase: Phase 4
Study type: Interventional

This is a 24 week, multicenter, randomized, double-blind, parallel group, placebo-controlled study to investigate the effects of saxagliptin and sitagliptin on cardiac dimensions and function in patients with type 2 diabetes (T2DM) mellitus and heart failure (HF).

NCT ID: NCT02915861 Completed - Scrub Typhus Clinical Trials

Eschar Investigations in Scrub Typhus

EXIST
Start date: June 30, 2017
Phase:
Study type: Observational

This is an observational study of patients with scrub typhus (rapid diagnostic test/quantitative polymerase chain reaction (RDT/qPCR) positive) and an inoculation eschar present on examination, recruited from Chiangrai Prachanukroh Hospital, North of Thailand. In this study, we aim to: - Investigate relevant pathogen dissemination dynamics, early innate immune response, and pathogen-host interactions in scrub typhus using a minimal set of easily accessible samples; the inoculation eschar (crust or biopsy), whole blood and - where possible - a lymph node fine-needle aspiration (FNA). - Determine the potential use of the inoculation eschar for improving early diagnostics and assessing the diversity of human pathogenic strains; by evaluating non-invasive swabs and scrapings, as well as biopsies for molecular diagnostics templates. - Dissect the underlying patho-biology associated with the inoculation eschar and in a subgroup, including the draining lymph node; by defining the spectrum of infected cells via microscopy and double-immune labeling; by determining cytokine and RNA gene expression profiles in blood peripheral blood mononuclear cell (PBMCs) and eschar samples. Data sharing: No future analysis or study of legacy data/specimens including data sharing for purposes not specified in the protocol will be done without seeking further regulatory (EC/IRB) approval - Any requests for data sharing will be considered by MORU's data sharing committee - Any data subsequently shared will be anonymised and will not include personal identifiers

NCT ID: NCT02910596 Completed - Bladder Dysfunction Clinical Trials

Effectiveness of Bethanechol Chloride and Early Bladder Training for Prevention of Bladder Dysfunction After Radical Hysterectomy in Cervical Cancer Stage IB - IIA

Start date: October 1, 2016
Phase: Phase 4
Study type: Interventional

Compare the effectiveness of bethanechol chloride and early bladder training for prevention of bladder dysfunction after radical hysterectomy in cervical cancer stage IB - IIA.